On the basis of these results, atezolizumab was the first ICI approved for adjuvant use in resected, early-stage NSCLC, though indications in Canada and Europe are limited to patients with PD-L1 expression ≥ 50% and differ from that in the United States (US; expression ≥ 1%) [38,39,40]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.